All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells

Author(s): Jing Chen, Jun Wu1 and Jiang Cao*
Clinical Research Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, 1Xuancheng Vocational and Technical College, Xuancheng 242000, Anhui Province, China

Correspondence Address:
Clinical Research Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China, E-mail: caoj@zju.edu.cn


In this investigation, a DNA sequence was designed and synthesized by joining coding regions of soluble programmed cell death-1 and T-cell immunoglobulin and mucin-3 domains and cloned into the lentiviral expression vector pLVX-IRES-ZsGreen1. After infection of the recombinant lentivirus into HEK 293T cells, the recombinant fusion protein, designated as sP1T3, was successfully expressed as detected by Western blotting. Binding assay was performed by incubating the cell lysate with cancer cells, which have high expressional levels of PD-L1/2 and galectin 9 and subsequent fluorescent staining showed strong membranous signals compared to negative controls using cell lysate without sP1T3, suggesting specific binding of sP1T3 to these ligand-expressing cancer cells. The recombinant fusion protein sP1T3 provided a useful tool for studying the effect of dual-blockade of immune checkpoint and its potential in targeted immunotherapy of cancer, which needs further investigation.

Full-Text | PDF

 
 
Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report